



RNS Number : 6760A  
Roquefort Therapeutics PLC  
26 September 2022

26 September 2022

**Roquefort Therapeutics plc**  
("Roquefort Therapeutics" or the "Company")

**Director/PDMR Shareholding**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Dr Darrin M Disley OBE, a Non-Executive Director has purchased ordinary shares in the Company in the market, as detailed below:

<b>Name</b>	<b>Number of Ordinary Shares</b>	<b>Average Price Paid Per Share</b>	<b>Total Consideration Paid</b>
Darrin Disley	515,913	7.7 pence	£39,999.93

Following the above purchase of shares, Darrin Disley holds interests in the following Company securities:

<b>Name</b>	<b>Number of Ordinary Shares Held</b>	<b>% of Issued Share Capital</b>
Darrin Disley	1,225,966	0.95%

**Enquiries:**

**Roquefort Therapeutics plc**

Stephen West (Chairman) / Ajan Reginald (CEO) +44 (0)20 3290 9339

**Hybridan LLP (Joint Broker)**

Claire Louise Noyce +44 (0)203 764 2341

**Optiva Securities Limited (Joint Broker)**

Christian Dennis +44 (0)20 3411 1881

**Buchanan (Public Relations)**

Ben Romney / Jamie Hooper / George Beale +44 (0)20 7466 5000

LEI: 254900P4SISIWOR9RH34

### **About Roquefort Therapeutics**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- MK cell therapy with direct and NK-mediated anti-cancer action; and
- siRNA targeting novel STAT-6 target in solid tumours showing significant *in vivo* efficacy.

For further information on Roquefort Therapeutics, please visit [www.roquefortplc.com](http://www.roquefortplc.com) and @RoquefortTherap on Twitter.

*This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").*

**The notification below, made in accordance with the requirements of the UK MAR, provides further detail:**

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS  
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY  
ASSOCIATED WITH THEM

- 1 Details of the person discharging managerial responsibilities / person closely associated**  
a) Name Dr Darrin M Disley
- 2 Reason for the notification**  
a) Position/status Non-Executive Director  
b) Initial notification /Amendment Initial
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  
a) Name Roquefort Therapeutics plc  
b) LEI 254900P4SISIWOR9RH34
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**
- |  |   |           |
|--|---|-----------|
| a) Description of the financial instrument, type of instrument | Ordinary shares of £0.01 par value        |           |
| Identification code  | ISIN: GB00BMDQ2T15                        |           |
| b) Nature of the transaction                                   | Purchase of 515,913 ordinary shares       |           |
| c) Price(s) and volume(s)                                      | Price(s)                                  | Volume(s) |
|  | 7.7 pence per share                       | 515,913   |
| d) Aggregated information                                      |   |           |
| - Aggregated volume  | - 515,913                                 |           |
| - Price  | - 7.7p                                    |           |
| e) Date of the transactions                                    | 26 September 2022                         |           |
| f) Place of the transactions                                   | London Stock Exchange (XLON); Main Market |           |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBXGDCGDDDDGDL  
Anonymous (not verified)  
Director/PDMR Shareholding  
32987947  
A  
Mon, 09/26/2022 - 14:30  
LSE RNS  
Directors' Dealings  
ROQ